RingelMD, SosaJA, BalochZ, et al.2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid2025;35(8):841-985; doi: 10.1177/10507256251363120.
2.
NCCN Guidelines® insights: thyroid carcinoma, version 1.2025; doi: 10.6004/jnccn.2025.0033.
3.
BoucaiL, ZafereoM, CabanillasME. Thyroid cancer: a review. JAMA2024;331(5):425-435; doi: 10.1001/jama.2023.26348.
4.
De LeoA, Di SimoneE, SpanoA, et al.Nursing management and adverse events in thyroid cancer treatments with tyrosine kinase inhibitors: a narrative review. Cancers (Basel)2021;13(23):5961; doi: 10.3390/cancers13235961.
5.
TaharaM, KiyotaN, HoffAO, et al.Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer2021;147:51-57; doi: 10.1016/j.ejca.2020.12.032.
6.
SchlumbergerM, TaharaM, WirthLJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med2015;372(7):621-630; doi: 10.1056/NEJMoa1406470.
7.
SabaNF, IsmailaN, AdkinsD, et al.Systemic treatment of thyroid cancer: ASCO guideline. J Clin Oncol2026;44(14):1349-1372; doi: 10.1200/JCO-26-00235.
8.
BonichonF, de BaereT, BerdelouA, et al.Percutaneous thermal ablation of lung metastases from thyroid carcinomas. a retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. Endocrine2021;72(3):798-808; doi: 10.1007/s12020-020-02580-2Epub 2021 Mar 26. PMID: 33770383.
9.
PalmaDA, OlsonR, HarrowS, et al.Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol2020;38(25):2830-2838; doi: 10.1200/JCO.20.00818.
10.
AvramAM, GiovanellaL, GreenspanB, et al.SNMMI procedure standard/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med2022;63(6):15N-35N.
11.
PorcelliT, SessaF, LuongoC, SalvatoreD. Local Ablative therapy of oligoprogressive TKI-treated thyroid cancer. J Endocrinol Invest2019;42(8):871-879; doi: 10.1007/s40618-019-1001-x.
12.
SaltikiK, KarapanouO, KantrevaK, et al.Local treatments and TKI efficacy in radioiodine refractory differentiated thyroid carcinoma patients: a single center experience. Endocr Relat Cancer2025;32(4):3240024; doi: 10.1530/ERC-24-0024.
